Tenderwize
Zurück zur Suche

Omalizumab Discount Agreement Open House

Techniker Krankenkasse·Hamburg, Germany·Deadline Jun 30, 2028 · 676 days left·Open·Supplies
Registrieren zum SpeichernOpen documents
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 18 Omalizumab

60/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

60 / 100

Komplexität

20 / 100

Risikofaktoren

No indication of estimated contract value or expected volume; revenue depends on actual prescriptions and number of par...

The notice explicitly states this is not a public procurement under EU directives; legal remedies lie with social court...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Jun 2028
  • Conclusion of discount agreements (Rabattverträge) for the active substance Omalizumab
  • Standardized contract terms no individualized negotiations
Vollständige Zusammenfassung anzeigen

Open house procedure by Techniker Krankenkasse (TK) for discount agreements (Rabattverträge) on the active substance Omalizumab. The procedure allows any qualified pharmaceutical entrepreneur to join at any time during the contract term (max 24 months until 30.06.2028). No exclusivity, no individual negotiations, and no estimated value provided. Eligibility requires being a pharmaceutical entrepreneur with a valid marketing authorization for the product. Award criteria are not specified. Submission is via email (with qualified electronic signature) or postal mail. Important: This is not a public procurement in the traditional sense; legal remedies lie with social courts, not procurement chambers.

Risiken

No indication of estimated contract value or expected volume; revenue depends on actual prescriptions and number of par...

The notice explicitly states this is not a public procurement under EU directives; legal remedies lie with social court...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Must be a pharmaceutical entrepreneur under § 4 Abs. 18 AMG with a valid marketing authorization for Omalizumab

Eligibility

  • Must submit a self-declaration (Anlage 4) confirming eligibility and reliability

Administrative

  • Contract can be signed at any time during the term but for timely inclusion in pharmacy software documents must be received by the 3rd of the previous month

Anforderungen können unvollständig sein.

Zuschlagskriterien

Lot 1

No award criteria specified; the procedure is open to all qualified participants with standardized conditions.

Auftraggeber

Ort

Hamburg, DEU

Kennung

992-80116-93

Tätigkeit

Health

Lose (1)

LOT-0001

Omalizumab Discount Agreement Open House

Single lot covering all discount agreements for Omalizumab. The TK aims to conclude rebate contracts with all eligible pharmaceutical entrepreneurs under § 130a Abs. 8 SGB V.

SuppliesEU fundedElectronic submission

Ort

DE600, Germany

Dauer

Jun 2026 - Jun 2028

Kategorie

Pharmaceutical products

Zuschlagskriterien

No award criteria specified; the procedure is open to all qualified participants with standardized conditions.

Frist

Deadline Jun 30, 2028

Vergabedetails

Veröffentlichungsdatum
20 May 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
349347-2026

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3